NGVT

Several events impacted Ingevity's stock in the past six months. In Q1 2026, Ingevity reported adjusted EPS exceeding expectations but revenue fell short, causing a 4.93% stock decline due to revenue miss and negative free cash flow concerns. The company strategically sold its Ozark Materials road markings business for approximately $65 million in April 2026, a move that investors viewed positively, pushing shares near their 52-week high. In January 2026, Ingevity completed the sale of its North Charleston Crude Tall Oil Refinery Assets and most of its Performance Chemicals Industrial Specialties Product Line for $110 million, aiming to simplify and streamline its business. Q2 2026 earnings in July 2026 saw both EPS and revenue beat estimates, with adjusted sales growing over 5% across all segments despite a 5% net sales decline due to divestiture, and adjusted EBITDA increasing by 14%. Additionally, in February 2026, the Federal Circuit affirmed an $85 million antitrust judgment against Ingevity in favor of BASF for unlawful tying, which Ingevity had already accrued and expected to pay in Q2 2026, impacting near-term cash.